Panbela Therapeutics logo
  • About Us
    • Company Overview
    • Management
    • Board of Directors
  • Our Science
    • Overview of Assets
    • Science
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Newsroom
    • Press Releases
    • Events & Presentations
  • Investor Relations
    • Corporate Governance
    • Financial Information
    • Annual Reports & Proxy Statements
    • Investor Contact Info
  • Contact

Our Science

  • Overview of Assets
  • Science
  •  – Polyamines
  •  – Polyamine Metabolic Inhibitor Technology
  • Pipeline
  • Clinical Trials
  •  – Ivospemin
  •  – Flynpovi
  • Expanded Access Policy

Quick Links

  • Home
  • About Us
  • Our Science
  • Newsroom
  • Investor Relations
  • Contact

Contact

ir@panbela.com
 
Sign up to receive press releases via email:

News & Events

Panbela Announces Pricing of Approximately $6 Million Public Offering

Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Provides Business Update and Reports Q2 2022 Financial Results

Copyright ©2022 Panbela Therapeutics, Inc. All Rights Reserved.